Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

it’s been a particular struggle for his Medicare patients. Medicare does allow coverage of Ozempic for patients diagnosed with type 2 diabetes and cardiovascular disease through Medicare Part D ...

(Juliana Yamada / Los Angeles Times via Getty Images) You may have heard of “Ozempic face,” “Ozempic butt” and “Ozempic finger,” three things that I have written about previously in ...

The increase in the Medicare Advantage enrollment over time may have affected follow-up trends. Follow-up for patients in long-term care nursing homes or those discharged to long-term care ...

Novo Nordisk, which manufactures Ozempic, Wegovy and Saxenda, and Eli Lilly, which manufactures Mounjaro, both stress that patient safety is their top priority, and that they actively collect ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

That, in turn, could cause sites to close even as patient demand for infusion drugs grows. Currently, Medicare compensates infusion centers for purchasing, managing, and administering intravenous ...

Novo Nordisk was previously sued in 2023, along with competitor Eli Lilly, by a patient with severe gastrointestinal side effects after taking Ozempic and Lily's Mounjaro. That lawsuit is being ...

All patients were Medicare beneficiaries, 88.2% of whom were older than 65 years. Of the 1594 patients, 652 were identified as having stage 2 hypertension based on the initial reading.

WASHINGTON, DC—A glimpse into PCI outcomes for Medicare patients treated at ambulatory surgical centers (ASCs) shows that, after the Centers for Medicare & Medicaid Services (CMS)’s decision to ...